Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470970) titled 'A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)' on March 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: EMD Serono Research & Development Institute, Inc.
Condition:
Systematic Lupus Erythematosus
Cutaneous Lupus Erythematosus
Intervention:
Drug: Enpatoran
Drug: Placebo
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 27, 2026
Ta...